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BULLETED STATEMENT 
 
What's already known about this topic? 
• Children with any of  type of epidermolysis bullosa (EB) are at higher risk of developing 
oropharyngeal lesions, involving either hard or soft tissues. 
• Very few reports have been published aimed at developing an EB scoring system, giving  little, 
if any, weight to the oropharyngeal component. 
What does this study add? 
• This study provides a new, objective, easy to perform, and reproducible scoring system for the 
oropharyngeal component in EB children, which has demonstrated an excellent inter- and intra-
observer reliability.  
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ABSTRACT 
 
Background: Epidermolysis bullosa (EB) is a rare genetic disorder characterized by constant 
formation of mucocutaneous blisters upon trivial trauma. All four EB types may show oropharyngeal 
lesions involving either hard or soft tissues. Currently, there are very few data on EB scoring including 
the oropharyngeal cavity. 
Objectives: To set up an oropharyngeal severity score that was objective, valid, reliable, reproducible, 
easy to perform, and appropriate for all EB types. 
Methods: In this multicentric study, oral medicine specialists developed a new score, the 
Epidermolysis Bullosa Oropharyngeal Score (EBOS). This measured oropharyngeal disease activity 
(erythema, atrophy, blisters, erosion/ulceration) and structural damage (microstomia, ankyloglossia, 
scarring phenotype beyond microstomia and ankyloglossia, enamel hypoplasia). It was tested on 92 
patients with different types/subtypes of EB, and inter- and intra-observer reliability were assessed. 
Results: The EBOS mean total score was 12.9±10.9 (range 0–33.5). Both inter-and intra-observer 
reliability for total score on all EB patients were considered excellent (ICC: 0.94; 95% confidence 
interval (CI): 0.90–0.96 and ICC: 0.90; 95%CI: 0.84–0.94, respectively). Even analyzing each single 
parameter of the disease activity and structural damage, a substantial-excellent correlation was found in 
the inter-observer (except for four sites) and intra-observer reliability. A significant correlation was 
found between EB types/subtypes and the EBOS median score (p< .001), but not between age and the 
EBOS mean total score in each group. 
Conclusions: The EBOS score seems to represent an instrument capable to truly quantify the 
oropharyngeal severity in different types/subtypes of EB, demonstrating an excellent inter- and intra-
observer reliability.  
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INTRODUCTION 
 
Epidermolysis bullosa (EB) encompasses a group of inherited mucocutaneous disorders 
characterized by the occurrence of blisters onto the skin and mucous membranes following mild 
mechanical trauma.1 Recently, EB has been classified in four major types, based on the split at the 
ultrastructural level: intraepidermal or epidermolytic (EB simplex [EBS]), intra-lamina lucida or 
lucidolytic (Junctional EB [JEB]), sub-lamina densa or dermolytic (Dystrophic EB [DEB]), and mixed 
(Kindler syndrome), and about 30 different subtypes.2 
Many EB patients may suffer from systemic complications and mucosal lesions, such as genital, 
ocular, oropharyngeal ones.3-5 These may affect both hard and soft tissues, showing different features 
and degrees of severity.6  In all EB types oral soft tissue are fragile, resulting in frequent blister and/or 
erosion formation, accompanied, in some EB subtypes, by a scarring phenotype and, although rarely, 
oral milia.7-10 Similarly, oral hard tissues may show either a marked developmentally compromised 
enamel or minor structural defects with areas of surface pitting and furrowing.11-15 
Although until now no consensus statement on EB severity score has been established, two 
reports have been published aimed at developing an EB scoring system.16,17 These attempted to develop 
a method of scoring EB severity, evaluating too many variables (skin, height, weight, mucous 
membranes, nutritional status, cancer, etc), and giving little, if any, weight to the oropharyngeal 
component. Hence, the need to develop an independent mucosal scoring system, because a “single all-
inclusive” score might be inadequate, as unable to truly reflect the severity of clinical conditions and 
correlation with disease prognosis. Our concern is that the oropharyngeal involvement has been 
previously16,17 evaluated solely based on subjective clinician's observations and patient’s reports 
(presence/absence of blisters/erosions over an “undefined” period of time, e.g., always, several per 
month,7 occasional, frequent, persistent8). Consequently, this should render these scoring systems less 
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reliable and reproducible, causing the notion of “score” to collapse.  
Considering the importance and impact of the oropharyngeal component on EB patients’ global 
health, we have developed a new separate score, called Epidermolysis Bullosa Oropharyngeal Severity 
Score (EBOS). Our purpose was to quantify and monitor the oropharyngeal involvement with an 
instrument that was as much as possible: (i) objective, in order to guarantee an effective and practical 
report of clinical signs far from subjective patient’s perception; (ii) valid, with content validity 
evaluated by experts in the field of oral medicine; (iii) reproducible and reliable worldwide among the 
same and different oral health care providers (oral medicine specialists, dermatologists, 
otorhinolaryngologists, paediatricians); (iv) easy to perform, so that to calculate the total score very 
quickly and, then, acceptable for patients, and (v) appropriate for all EB types/subtypes. 
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MATERIALS AND METHODS 
 
Study design and Patients 
This was a multicentric study collecting data from 92 EB patients between September 2010 and 
September 2011 coming from the EB Clinic at Lucile Packard Children’s Hospital, the adult Bulluos 
Disease Clinic, Stanford, California (USA), and Dermatology Clinic at Istituto Tecnologico y de 
Estudios Superiores and D.eb.RA. Mexico Foundation, Monterrey (Mexico). The Department of 
Orofacial Sciences, School of Dentistry, University of California, San Francisco (USA), and the Oral 
Medicine Unit, Department of Odontostomatological and Maxillofacial Science, Federico II University 
of Naples, Naples (Italy) cooperated with them. All patients provided their written informed consent. 
This study was approved by the Ethical Committees of Stanford University and Instituto Tecnologico 
in Monterrey. 
All patients were enrolled based on the following inclusion criteria: 
1. Patients of both gender, all age and race, with the presence of typical mucocutaneous lesions of 
any EB type/subtype, as previously reported.2 
2. Diagnosis of EB based on skin biopsy with a routine histology and immunofluorescence antigen 
mapping (IFM), and/or, whereas available, electron microscopy (EM) and/or DNA analysis. 
3. Patients able to give consent if older than 18 years. For minor patients consent was given by 
their parents or guardian. 
At the time of admission exclusion criteria encompass: 
1. Patients who had used topical corticosteroids and/or topical and/or systemic antifungal therapy 
during the previous 3 weeks, as capable to substantially modify the oropharyngeal clinical 
appearance.  
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2. Patients with present or past history of oropharyngeal malignancy and/or potentially malignant 
disorders. 
 
Generation and refinement of scoring items  
In origin, the EBOS included only the number of sites involved, plus microstomia, ankyloglossia, 
and enamel hypoplasia. After an accurate revision of the literature and discussion among authors, this 
score was abandoned as considered not really indicative of disease severity. Content validity was 
accurately revised and the EBOS was refined by introducing the nature of oropharyngeal lesions and 
the presence of a scarring phenotype in other parts of the oral cavity, beyond microstomia and 
ankyloglossia.  
Eventually, a more appropriate EBOS was re-designed, including 2 different scores: disease 
activity and structural damage (Figure 1). 
The first evaluated only clinical signs, as objective findings.  Specifically, four were identified as 
key features of disease activity: erythema, atrophy, blister, erosion/ulceration. These signs were not 
scored in terms of quality (mild, moderate, severe), because too subjective among physicians, or 
quantity (number of lesions), because too difficult and confusing to calculate, as usually oropharyngeal 
lesions tend to be confluent. Clinically, atrophy in EB appeared similar to that seen in progressive 
systemic sclerosis, i.e., with vestibule obliteration, depapillated tongue, disappearance of palate rugae, 
blanching of buccal mucosa and/or soft palate. 
The second evaluated the presence or absence of four parameters: microstomia, ankyloglossia, 
presence of intraoral scars beyond microstomia and ankyloglossia, such as vestibule obliteration, and 
enamel hypoplasia. These clinical features were considered more permanent, as a part of a previous 
damage and, therefore, not necessarily reflecting current disease activity. Microstomia was evaluated 
with the maximal mouth opening by measuring the distance from the marginal edge of the central 
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upper to lower incisors, along the inter-incisal line. In case of missing teeth in one or both jaws, 
measurement was done considering the distance between edentulous alveolar ridges, passing through 
the two craniomethic points: nasion and gnathion. A patient with a maximal aperture less than 35mm 
was considered as having microstomia, as previously reported.18 Ankyloglossia was evaluated by the 
ability of each patient to protrude his tongue over the lower incisors or edentulous alveolar ridge, move 
it over to the left and right side, and reach the premaxilla with the tip of the tongue. A patient unable to 
perform at least two of the above-mentioned movements was considered as having ankyloglossia.  
 
The EBOS score  
In order to increase the score sensitivity, the oropharyngeal cavity was divided in 13 different 
anatomic sites. The disease activity score evaluated each site affected by one or more clinical signs. We 
decided to assign 1 point to each clinical sign present in each anatomical site, leading to a total score 
ranging from 0 to 52. Conversely, the structural damage score evaluated the presence or absence of the 
4 structural damages, assigning 2 point each  to a total score ranging from 0 to 8 (Figure 1).   
Grading system was based on the sum of both scores, reaching a final total score ranging form 0 
to 60, rather than on virtually impossible task of determining accurately the percentage of each site 
involved by each type of lesion. 
 
Inter- and Intra-observer reliability 
Inter-observer reliability was evaluated in all patients, who were scored independently by two 
different physicians on the same day. Conversely, intra-observer reliability was assessed on a randomly 
selected group of patients (34 out of 92). Such patients were asked to come back after three hours and 
not to eat anything, use any kind of topical/mouthwash medication, drink alcohol or smoke cigarettes. 
In order to minimize recall bias, during the three hours of interval, the scorers were asked to see 100 
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consecutive pictures of patients with oropharyngeal blistering diseases, such as pemphigus vulgaris, 
mucous membrane pemphigoid, erosive lichen planus. Eventually, each patient was seen twice by the 
same physicians, and, on the second round, in a different and random order compared to his/her first 
visit. Time for scoring was also recorded. 
 
Statistic analysis 
Descriptive statistics of demographic characteristics and EB type/subtype distribution was 
calculated as mean ± standard deviation. The EBOS score was calculated as a mean value of the scores 
from two investigators for all 92 patients and the subgroup of 34 patients. Means, medians and 
interquartile ranges (IQR) in each EB type/subtype and each oropharyngeal site were also calculated. 
Inter- and intra-observer reliability for disease activity and structural damage (separately and grouped) 
were calculated by intraclass correlation coefficient (ICC) along with 95% confidence interval (CI). 
The ICC values were interpreted as follows: 0.00–0.20=poor agreement, 0.21–0.40=fair agreement, 
0.41–0.60=moderate agreement, 0.61–0.80=substantial agreement, 0.80–1.00=excellent agreement.19 
Spearman’s correlation coefficient was used to assess the relationship between age and the EBOS mean 
total score, and non-paramentric Kruskal-Wallis ANOVA was used to assess the relationship between 
EB types/subtypes and the EBOS median total score. P-values of less than .05 were considered 
significant. Statistical analyses were performed using the SPSS software (SPSS for Windows, version 
17.0; SPSS Inc, Chicago, IL – USA. 
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RESULTS 
Patients’ characteristics 
During the study period ninety-two patients (48 [52.2%] females and 44 [47.8%] males) with a 
mean age of 15.4 years (range: 2 months–63 years) (SD: 14.1; 95% CI: 12.4 – 18.3) with different EB 
types/subtypes (Table 1) were tested with the EBOS. 
 
Activity and Damage Score Distribution 
The EBOS mean total score ± standard deviation (SD) was 12.9 ± 10.9 (range 0–33.5), while the 
mean total score ± SD for disease activity and structural damage was 10.1 ± 8.5 (range: 0–27.5) and 2.8 
± 2.6 (range: 0–6), respectively. 
The range of EBOS mean score was 0-33.5 out of a possible 60 maximum score, with a median 
of 13.00 and an IQR of 20.50 (Table 2; Figure 2), whereas in the sub-sample (N=34) the range of mean 
score on time 1 (test) was 0 – 24.5, with a median of 13.00 and an IQR of 18.50 and on time 2 (re-test) 
0 – 26.5 with a median of 11.50 and an IQR of 16.50 (Table 2; Figure 3). The highest EBOS score by 
site was measured for tongue, while the lowest for upper and lower fornices, either on total sample 
(Table 3) or sub-sample (Table 4).  
 
Inter- and Intra-observer reliability 
The inter- and intra-observer reliability for total score on all EB patients were excellent 
(ICC:0.94; 95%CI: 0.90–0.96 and ICC:0.90; 95%CI: 0.84–0.94, respectively). Even a comparison 
between the mean total score of RDEB patients versus all other EB patients showed an excellent 
agreement, unlike the total score on all other EB patients in the inter-rater assessment (ICC:0.58; 
95%CI: 0.30–0.77) (Table 5). 
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Analyzing disease severity, either in the inter- or intra-rater assessment, lower lip reached the 
highest agreement (ICC:0.89; 95%CI: 0.84–0.92; ICC:0.91; 95%CI: 0.83–0.95, respectively), followed 
by tongue (ICC:0.87; 95%CI: 0.81–0.91) in the inter-rater, and by hard palate (ICC:0.87; 95%CI: 0.76–
0.93) in the intra-rater (Table 3 and 4). As far as structural damage is concerned, microstomia and 
ankyloglossia either in the inter-rater (ICC: 0.93; 95%CI: 0.90–0.97; ICC: 0.89; 95%CI: 0.84–0.93, 
respectively), or in the intra-rater assessment (ICC: 0.94; 95%CI: 0.89–0.97; ICC: 0.94; 95%CI: 0.88–
0.97, respectively) reached the highest agreement (Table 3 and 4). 
 
Correlation of EBOS score with EB types/subtypes and age. 
Lastly, a significant correlation was seen between EB types/subtypes and the EBOS median score 
(K-W ANOVA=71.626; P< .001) (Table 2), but not between age and the EBOS mean total score. 
Indeed, there was a decline of score in EBS and JEB patients with age (EBS: ρ= –0.52,  p= .107; JEB: 
ρ= –0.80, p= .13 ) and an increase in the rest of EB patients (DDEB: ρ= 0.20, p= .42; RDEB–O: ρ= 
0.20, p= .48; RDEB-sev gen: ρ= 0.03, p= .85), but none of them were statistically significant.  
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DISCUSSION 
  
Since its first description in 1879,20 the oropharyngeal involvement in EB patients has always 
been one of the major concerns for every clinician,  and they still represent one of the most important 
and challenging clinical manifestations, either in terms of evaluation, prognosis, and treatment.  If, on 
the one hand, some medical/surgical treatments21-29 have been attempted in order to improve EB 
patients’ oral conditions, on the other hand, evaluation and prognosis of oropharyngeal component in 
EB still remain an enigma.  
All EB types/subtypes may virtually experience all four clinical signs evaluated in this study, 
although with different frequency and extension: some had no or a very few and mild lesions and some 
others had many severe and disfiguring ones. Therefore, we thought that it was important to have an 
instrument capable to distinguish between active lesions and damage, in order to improve the global 
assessment of oropharyngeal severity either in hospital setting or in clinical trial of some potential 
medications. To the best of our knowledge, there is no published data on the grading of the individual 
clinical signs in each single oropharyngeal site in EB. 
Our results on 92 EB patients showed that the EBOS has an excellent inter- and intra-observer 
reliability on both total and partial score of disease activity and structural damage score, with a median 
score changing significantly upon different EB type/subtypes (p < .001) (Table 2), unlike age which 
showed no correlation with the EBOS mean total score. 
Considering also that we expected that RDEB patients were more severe, in order to reduce the 
bias of sample dilution, we divided all 92 patients in 2 sub-groups: all RDEB patients versus all other 
EB type/subtype patients. Even in this case the intra-rater reliability was excellent in both groups, while 
the inter-rater reliability was excellent for RDEB patients and moderate for all other EB patients (Table 
5). It is likely that it is easier for 2 different physicians to detect gross and more widespread lesions, as 
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usually seen in RDEB patients, rather than subtle and sporadic lesions, as usually seen in the rest of EB 
patients. Interestingly, RDEB patients reached the highest EBOS mean total score versus all other EB 
types/subtypes (Figure 2) as supposed, in line with previous reports.6-10,18,21 Therefore, this result would 
support the EBOS validity. 
The inter-rater reliability demonstrated to be poor-fair for upper and lower fornices (ICC: 0.05 
and 0.10, respectively), floor of the mouth (ICC: 021) and oropharynx (ICC: 0.34) (Table 3), but was 
substantial-excellent either for disease activity or structural damage in the intra-rater assessment. 
Unfortunately, two sites (soft palate and oropharynx) and one permanent damage (enamel hypoplasia) 
were unable to be evaluated, since date were absent for both scorers or present just for one. All these 
disagreements between the 2 scorers might reflect their different capability to detect and classify a 
lesion. For instance, the different use of a light might have led to an under or over-estimation of some 
clinical signs, such as erythema, whose detection largely relies upon light direction, mostly in the most 
posterior oropharyngeal sites, like soft palate and oropharynx. Lastly, the EBOS was a very quick and 
easy to use tool, as time for record ranged from 1 to 5 minutes. 
Two parameters were not included in the EBOS: first, the presence of oropharyngeal malignancy, 
because we thought that this needed a separate evaluation, considering how severe and worse in terms 
of prognosis could be. Also, to the best of our knowledge, there are only two reports of EB and 
oropharyngeal cancer 30-31 and, therefore, this would have very likely resulted in adding an unvalidated 
parameter. If this means that EB patients very rarely develop oropharyngeal cancer or simply such 
lesions are undetected or underestimated remains unknown. In our study, none of 92 patients presented 
with any oropharyngeal malignancy and/or potentially malignant disorders. 
Second, the presence of dental caries and/or periodontal disease (with subsequent dental loss) 
was not included, as not directly related to the disease. Indeed, although the percentage of dental caries 
seemed to be higher in EB patients versus a control group, it was not related to the disease.32 However, 
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it would be necessary to compare EB patients with a control group selected from different social 
background to really ascertain the incidence in both groups.  
Lastly, we decided to not evaluate associated symptoms, such as pain and/or discomfort, and 
daily activities impairment, such as ability to eat, drink, or speak in this score, because these were 
considered subjective parameters to be evaluated in a study on the quality of life and quality of oral 
health. 
This study has several limitations. The sample size was small and the number of EB subtypes was 
limited. It would be preferable to test this score in different hospital settings on a larger sample and 
higher variety of different EB subtypes. Another limitation could be the evaluation of inter- and intra-
observer reliability by only two physicians. However, this was due to on purpose in order to not cause 
an excessive pain and unpleasant burden with multiple visits by more than two physicians. In addition, 
the intra-observer reliability was only tested on a part of the total sample.  
Despite all these limitations, the EBOS may offer many important future perspectives. First, a 
validated scoring system capable of objectively evaluating the oropharyngeal disease severity might be 
useful even longitudinally to better understand the disease progression, thereby representing a valid 
prognostic tool. Indeed, the EBOS might be used to follow EB patients from their birth and assess how 
oropharyngeal cavity is going to be affected over time in order to possibly prevent any structural 
damage and ameliorate disease activity.  Second, it appears that the severity of oropharyngeal lesions 
increase with the severity of cutaneous lesions3 and, therefore, it would be interesting to correlate the 
EBOS with other cutaneous score already present in the literature. Third, it would be interesting to 
correlate the EBOS with the type of mutations, in order to see whether or not there is an oropharyngeal 
phenotypic-genotypic correlation. Fourth, it would be useful to investigate any clinically meaningful 
change of the EBOS in response to medical and/or surgical oropharyngeal care interventions, 
particularly in clinical trials. 
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In conclusions, in this preliminary study the EBOS turned out to be a clinically valid and reliable 
tool to assess the oropharyngeal severity in EB patients. However, further investigations and 
refinements by other groups worldwide are strongly encouraged to better confirm our results. 
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Figure Legend. 
Figure 1. Epidermolysis Bullosa Oropharyngeal Severity score (EBOS). 
Figure 2.  Box plot analysis of EBOS total score distribution per EB type/subtype calculated on full 
sample of 92 patients. Lines in box denotes medians, bar include at most 1.5 of interquartile distance, 
difference between first and third quartile of score. Circle indicate value of the extreme outlier. 
Figure 3. Box plot analysis of EBOS total score distribution calculated on a subsample of 34 patients at 
time 1 (test) and time 2 (re-test) per EB type/subtype. Lines in box denotes medians, bar include at 
most 1.5 of interquartile distance, difference between first and third quartile of score. Circle indicate 
value of the extreme outlier.  
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